A detailed history of Jones Financial Companies Lllp transactions in Genmab A/S stock. As of the latest transaction made, Jones Financial Companies Lllp holds 479 shares of GMAB stock, worth $9,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares
479
Previous 400 19.75%
Holding current value
$9,101
Previous $9,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 05, 2025

BUY
$20.02 - $24.15 $1,581 - $1,907
79 Added 19.75%
479 $9,000
Q3 2024

Nov 12, 2024

BUY
$23.84 - $28.48 $2,646 - $3,161
111 Added 38.41%
400 $9,000
Q2 2024

Aug 14, 2024

BUY
$25.13 - $30.27 $7,262 - $8,748
289 New
289 $7,000
Q4 2023

Feb 13, 2024

BUY
$27.94 - $35.44 $251 - $318
9 New
9 $0
Q1 2022

May 02, 2022

SELL
$30.95 - $39.68 $2,971 - $3,809
-96 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$35.87 - $47.12 $3,443 - $4,523
96 New
96 $4,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $12.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Jones Financial Companies Lllp Portfolio

Follow Jones Financial Companies Lllp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jones Financial Companies Lllp, based on Form 13F filings with the SEC.

News

Stay updated on Jones Financial Companies Lllp with notifications on news.